HK Stock Market Move | INNOVENT BIO (01801) fell more than 8% in early trading, founder Yu Dechao recently reduced his holdings and cashed out approximately HK$1.21 billion.

date
10:33 15/05/2026
avatar
GMT Eight
Xinda Biotech (01801) fell more than 8% in early trading, as of the time of writing, down 7.61%, at HK$80.1, with a turnover of HK$8.45 billion.
INNOVENT BIO (01801) fell more than 8% in the morning session, dropping by 7.61% to HK$80.1 at the time of writing, with a turnover of HK$845 million. On the news front, INNOVENT BIO's founder, chairman and CEO, Yu Dechao, reduced his holdings by 1.353 million shares on May 11, 2026, at an average price of HK$89.362 per share, cashing out approximately HK$121 million. After the reduction, his shareholding dropped to 7.49%, remaining the largest shareholder. China Post Securities pointed out that INNOVENT BIO achieved a comprehensive turnaround in profit indicators for the first time in 2025, indicating that its business model has been validated and officially entered the WINOX era. The gross profit margin benefited from economies of scale and production efficiency improvements, with a year-on-year increase of +2.3 percentage points to 87.2%; revenue growth was strong, with sales and management expense ratio decreasing by -2.9 percentage points year-on-year to 48.0%, EBITDA increasing by +384% year-on-year to HK$1.99 billion, and cash and cash equivalents reaching HK$24.3 billion, equivalent to approximately US$3.5 billion, providing a solid guarantee for long-term development.